samedan logo
home > ebr > spring 2021 > expediting next-generation vaccine development using advanced analytical methods
European Biopharmaceutical Review

Expediting Next-Generation Vaccine Development Using Advanced Analytical Methods

The emergence of the COVID-19 pandemic has spurred wide interest in the development of new and novel vaccines and therapeutic drugs against viruses. In addition to the classical platforms (whole-inactivated virus; live-attenuated virus; protein subunit and virus-like particles), novel next-generation platforms (viral vector, DNA, RNA, and antigen-presenting cells) are some of the emerging areas. These next-generation vaccines are mainly focused on nucleic acids and can be developed based on sequence information alone. The advancement in high-throughput sequence technologies and bioinformatics offers invaluable knowledge on genomic characterisation. Bioinformatics insights like sequence similarity, phylogenomic, and computational structural biology have provided an in-depth understanding of the molecular and biochemical basis of infection, atomic-level recognition of the viral-host receptor interaction, functional annotation of important viral proteins, and evolutionary divergence across different strains. Due to the challenges in identifying the most effective vaccine candidates, technologies and methods that can accelerate and streamline further screening and characterisation will be critical in the speed to bring them to market.

Currently, various modern approaches are being used to target the most promiscuous antigenic epitopes from the virus proteome for accelerating vaccine development and production processes. Many of these are novel platforms with little pre-existing data on safety and efficacy in humans. Sartorius offers a diverse range of analytical technologies (including the Octet®, Incucyte®, the iQue®) that can facilitate the rapid and high-throughput characterisation of these molecules.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

The Sartorius Group is a leading international partner of biopharmaceutical research and the industry. With innovative laboratory instruments and consumables, the Group's Lab Products & Services Division concentrates on serving the needs of laboratories performing research and quality control at pharma and biopharma companies and those of academic research institutes. The Bioprocess Solutions Division, with its broad product portfolio focusing on single-use solutions, helps customers to manufacture biotech medications and vaccines safely and efficiently.
Print this page
Send to a friend
Privacy statement
News and Press Releases

Catalent Plans Multi-Phase, $100 Million Expansion of Italian Facility to Increase Biologics Manufacturing Capabilities in Europe

SOMERSET, N.J. – July 21, 2021 – Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that it will commence the first phase of a planned $100 million expansion program at its facility in Anagni, Italy, to add biologics drug substance manufacturing capabilities, supporting the growing European market demand for biologics manufacture and supply.
More info >>

White Papers

Speciality Logistics Outlook 2015

World Courier

To date, there are more than 178,000 registered clinical trials taking place across the globe, and global pharma’s volume has more than doubled over the last decade. With emerging markets showing explosive predictive growth through 2016, shippers and trial sponsors can expect continued regulatory and overall logistics complexities that foster demand for local, inmarket resources across the globe.
More info >>

Industry Events

Pharma Integrates 2021

16 November 2021, VIRTUAL CONFERENCE

Now in its tenth year, Pharma Integrates is a unique event bringing together pharma and healthcare leaders across the Pharmaceutical pipeline to address their needs, to share insights and create debate on crucial topics that influence the future of patient outcomes.
More info >>



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement